| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/21/2002 | WO2001070672A3 Compounds and methods to treat alzheimer's disease |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001068092A3 Glycogen phosphorylase inhibitor |
| 03/21/2002 | WO2001068034A3 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064252A3 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 03/21/2002 | WO2001064198A3 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 03/21/2002 | WO2001064197A3 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 03/21/2002 | WO2001064195A3 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001062725A3 Methods and compositions for inhibiting angiogenesis |
| 03/21/2002 | WO2001060991A3 Human kinases |
| 03/21/2002 | WO2001058954A3 Trade molecules and uses related thereto |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001051055A3 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 03/21/2002 | WO2001047935A3 Novel bisamidate phosphonate prodrugs |
| 03/21/2002 | WO2001043731A3 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage |
| 03/21/2002 | WO2001034196A3 Mixture containing rare earths and use thereof |
| 03/21/2002 | WO2001034135A3 Oncolytic combinations for the treatment of cancer |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001014372A3 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/21/2002 | WO2001010199A9 A knockout mouse for the tumor suppressor gene anx7 |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035386 Therapeutic light source and method |
| 03/21/2002 | US20020035260 4-aza-steroids |
| 03/21/2002 | US20020035243 Drug complexes |
| 03/21/2002 | US20020035240 Novel mammalian cell cycle protein |
| 03/21/2002 | US20020035153 Kits; containing a compound containing an oxamic acid group |
| 03/21/2002 | US20020035144 Solubility, bioavailability; antiinflammatory agents |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035130 Antidepressants, therapy for Parkinson's disease |
| 03/21/2002 | US20020035127 Phenylalanine derivatives |
| 03/21/2002 | US20020035125 Therapeutic combination |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035113 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use |
| 03/21/2002 | US20020035108 Method for treating allergies |
| 03/21/2002 | US20020035104 Integrin receptor inhibitors |
| 03/21/2002 | US20020035093 Methods for the administration of amifostine and related compounds |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | US20020035091 Administering thalidomide and irinotecan; avoiding adverse side effects associated with irinotecan |
| 03/21/2002 | US20020035090 Compositions and methods for the treatment of cancer |
| 03/21/2002 | US20020035083 CRF2 ligands in combination therapy |
| 03/21/2002 | US20020035072 Method for enhancing mutant enzyme activities in lysosomal storage disorders |
| 03/21/2002 | US20020035065 Selective MMP inhibitors having reduced side-effects |
| 03/21/2002 | US20020035064 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/21/2002 | US20020035046 Suitable for use in skin care applications, which effectively deliver and/or deposit various benefit agents into and onto the skin and which are relatively non-irritating |
| 03/21/2002 | US20020034821 Methods and compositions for enhancing the delivery of a nucleic acid to a cell |
| 03/21/2002 | US20020034800 Preferential bone marrow polypeptides; for generation of erythrocytes; for healing fractured bones |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | US20020034779 Novel argS |
| 03/21/2002 | US20020034778 Peptide; for use in drug screening; for use as a diagnostic tool; for use in the treatment of nervous system disorders |
| 03/21/2002 | US20020034772 Methods and compositions that affect melanogenesis |
| 03/21/2002 | US20020034764 Diarylsulfonylurea binding proteins |
| 03/21/2002 | US20020034758 Novel human genes and gene expressions products: II |
| 03/21/2002 | US20020034725 Sensitization of cells to radiation and and chemotherapy |
| 03/21/2002 | US20020034538 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations |
| 03/21/2002 | US20020034513 MHC complexes and uses thereof |
| 03/21/2002 | US20020034509 Methods and compositions for ameliorating the symptoms of sepsis |
| 03/21/2002 | DE10044905A1 (2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten (2-azabicyclo [2.2.1] hept-7-yl) methanol derivatives as nikontinische acetylcholine receptor agonists |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2687476A1 N-phenyl-2-pyrimidine-amine derivatives |
| 03/21/2002 | CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists |
| 03/21/2002 | CA2422828A1 Novel tumor-associated marker |
| 03/21/2002 | CA2422426A1 Polymorphic bone morphogenetic protein 2 |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422246A1 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists |
| 03/21/2002 | CA2422229A1 Calcium binding proteins |
| 03/21/2002 | CA2422152A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422068A1 Method for treatment of insulin resistance in obesity and diabetes |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2422044A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421652A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420529A1 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419224A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/21/2002 | CA2416563A1 Pharmaceutical composition having specific water activity |
| 03/21/2002 | CA2357467A1 Methods for treating osteoarthritis using an estrogen agonist/antagonist |
| 03/20/2002 | EP1188760A1 Ip3 receptor ligands |
| 03/20/2002 | EP1188754A1 Substituted pyrazole compounds |
| 03/20/2002 | EP1188747A1 Phenoxypropylamine compounds |
| 03/20/2002 | EP1188445A1 Drug composition containing lecithin-modified superoxide dismutase |
| 03/20/2002 | EP1188439A2 Cell differentiation induction with mevalonate and mevalonolactone derivatives |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187924A1 Substrate trapping protein tyrosine phosphatases |
| 03/20/2002 | EP1187923A1 Apoptosis inhibition by adenovirus e3/6.7k |